Overall, the results presented in this study suggest that the amplification/polysomy of the growth factor VEGFA is not a sufficient condition to determine the response to anti-angiogenic therapy with Ramucirumab, rather it is VEGFA protein overexpression in the tumor tissues associated with an induction of micro-vessels that leads to the therapeutic response in patients otherwise characterized by a poor prognosis. This evidence concerns the gene VEGFA and neoplasm.